PUBLIC COMPANY
save$BEAMBeam Therapeutics Inc.
$BEAM26.85-1.58%Cambridge, MA, USupdated 7h ago
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Preclinical4Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- —A Long-term Follow-up Study in Patients Who Received BEAM-101
- phase1This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
- phase2BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- phase2A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
- phase2A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 1, 26SELLEvans John M.· CEO−$739K↗
- Apr 1, 26SELLCiaramella Giuseppe· President−$290K↗
- Apr 1, 26SELLSimon Amy· Chief Medical Officer−$165K↗
- Apr 1, 26SELLBellon Christine· Chief Legal Officer−$146K↗
- Apr 1, 26SELLCavanagh Bethany J· SVP, Finance and Treasurer−$80K↗
- Mar 31, 26SELLEvans John M.· CEO−$569K↗
- Mar 30, 26SELLEvans John M.· CEO−$559K↗
- Feb 24, 26SELLCiaramella Giuseppe· President−$1.12M↗
routine RSU / option mechanics (6)
- Mar 31, 26option exerciseEvans John M. · CEO25,000 sh
- Mar 31, 26grantBellon Christine · Chief Legal Officer20,000 sh
- Mar 31, 26grantEmany Sravan Kumar · Chief Financial Officer31,750 sh
- Mar 31, 26grantSimon Amy · Chief Medical Officer31,750 sh
- Mar 31, 26grantEvans John M. · CEO90,000 sh
- Mar 31, 26option exerciseEvans John M. · CEO25,000 sh
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Beam Therapeutics Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaHematology 1Metabolic 1
News
- STAT+: The promise of radiopharmaceuticals smacks into safety concernsDespite excitement over the potential of radiopharmaceuticals as cancer treatments, drug developers are hitting new hurdles.stat · 1d ago
- Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employeesSeven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in th…biospace · 6d ago
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 7d ago
- STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plansThe FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.stat · 7d ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 14d ago
- STAT+: UnitedHealth’s questionable review, and more MA stars lawsuitsUnitedHealth touts a new home care audit, and more health insurers sue CMS over Medicare Advantage quality ratings.stat · 29d ago
- STAT+: All eyes on data on Biogen’s tau therapyThe year of daraxonrasib, a wearable for a myeloma drug, and more biotech news from The Readoutstat · 29d ago
- STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to comePancreatic cancer specialists are excited about the biggest breakthrough in the field in decades. They are also looking around the corner to what comes next.stat · 29d ago
- STAT+: Tau in the spotlight at Alzheimer’s conferenceFrom STAT's AAIC in 30 newsletter: Researchers focus on tau, and progress on crossing the blood-brain barrier.stat · 1mo ago
- STAT+: Roche ends Huntington’s gene-silencing programsARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readoutstat · 1mo ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that